Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040

Dow Jones

10/03

By Adriano Marchese

Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.

Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.

Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.

Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.

Dr. Reddy's wasn't readily available for comment.

Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 03, 2025 08:42 ET (12:42 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572507271"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572507271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572507271?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572507271","market":"hk","top_or_hot":-1,"title":"Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dr. Reddy's Laboratories won't market a generic version of Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' cholesterol drugs after a reaching a settlement. \n</p>\n<p>\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n</p>\n<p>\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n</p>\n<p>\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n</p>\n<p>\n  Dr. Reddy's wasn't readily available for comment. \n</p>\n<p>\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 03, 2025 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-03 20:42</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dr. Reddy's Laboratories won't market a generic version of Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' cholesterol drugs after a reaching a settlement. \n</p>\n<p>\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n</p>\n<p>\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n</p>\n<p>\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n</p>\n<p>\n  Dr. Reddy's wasn't readily available for comment. \n</p>\n<p>\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 03, 2025 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4523","symbol_name":"印度概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572507271","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572507271","pubTimestamp":1759495320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4523":"印度概念","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","BK4557":"大麻股","ESPR":"Esperion Therapeutics Inc.","BK4532":"文艺复兴科技持仓","BK4596":"哈里斯概念","RDY":"如瑞迪博士","BK4007":"制药"},"translate_title":"Esperion Therapeutics在2040年之前阻止Reddy博士的胆固醇药物仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5,"RDY":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement. \n\n\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n\n\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n\n\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n\n\n  Dr. Reddy's wasn't readily available for comment. \n\n\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2025 08:42 ET (12:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}